Chronic administration of coenzyme Q10 limits postinfarct myocardial remodeling in rats

Abstract

The effect of chronic coronary artery occlusion on the content of rat myocardial coenzymes Q (CoQ) and evaluation of the applicability of CoQ(10) for limiting postinfarct remodeling have been investigated. Left ventricle myocardium hypertrophy was characterized by the decrease in CoQ(9) (-45%, p < 0.0001), CoQ(10) (-43%, p < 0.001), and alpha-tocopherol (-35%, p < 0.05). There were no differences between the parameters of postinfarction and sham-operated rats in plasma. Administration of CoQ(10) (10 mg/kg) via a gastric probe for 3 weeks before and 3 weeks after occlusion maintained higher levels of CoQ in the postinfarction myocardium: the decrease in CoQ(9) and CoQ(10) was 25% (p < 0.05) and 23% (p < 0.05), respectively (versus sham-operated animals). Plasma concentrations of CoQ(10) were more than 2 times higher (p < 0.05). In CoQ treated rats there was significant correlation between plasma levels of CoQ and the infarct size: r = -0.723 (p < 0.05) and r = -0.839 (p < 0.01) for CoQ(9) and CoQ(10). These animals were also characterized by earlier and more intensive scar tissue formation in the postinfarction myocardium and also by more pronounced cell regeneration processes. This resulted in the decrease in both the infarct size (16.2 +/- 8.1 vs. 27.8 +/- 12.1%) and also mass index of left ventricle (2.18 +/- 0.24 vs. 2.38 +/- 0.27 g/kg) versus untreated rats (p < 0.05). Thus, long-term treatment with ubiquinone increases plasma and myocardial CoQ content and this can improve the survival of myocardial cells during ischemia and limit postinfarct myocardial remodeling.

HPLC estimation of coenzyme Q10 redox status in plasma after intravenous coenzyme Q10 administration

“…Экстракцию CoQ 10 из плазмы крови проводили по методике Lass и Sohal [13] с небольшими изменениями [14]. К плазме крови добавляли этанол и n-гексан (1:2:5), тщательно встряхивали в течение 10 мин, центрифугировали (4000 g) в течение 3 мин и отбирали верхний слой n-гексана.…”

Pharmacokinetics of coenzyme Q10

“…This is in line with published data indicating that plasma concentrations of coenzyme Q 10 are 2-2.5 times higher during long-term oral therapy with solubilized forms [4] and the bioavailability is 3-6 times higher in comparison with powder [6,12]. The pharmacokinetic advantages of solubilized form are responsible for its high efficiency as a cardioprotector: chronic oral treatment led to an increase of not only plasma levels of coenzyme Q 10 (2.5 times), but of also its concentration in rat myocardium, which improved survival of cardiomyocytes under conditions of ischemia and eventually limited the size of the postinfarction necrotic zone [2].…”

“…Kinetic curves of coenzyme Q 10 concentrations, mean for groups, for solubilized form (1) and powder(2). *p<0.00001, **p<0.001, ***p<0.05 compared to 2.…”

CoEnzyme Q10: A new horizon in the treatment of periodontal diseases

“…In a Study, solubilized coenzyme Q10 has shown better absorption, higher plasma concentration, and consequently better bioavailability which indicates that plasma concentrations of coenzyme Q10 are 2-2.5 times higher during long-term oral therapy with solubilized forms and the bioavailability is 3-6 times higher comparing with powder. (27)(28)(29)…”